Skip to content
    Reviews

    Precision Adjuvant Therapy in Resected GIST: Evidence-Based Genotyping and Dosing Strategies

    Huang et alCurrent Treatment Options in Oncology

    Precision Adjuvant Therapy in Resected GIST: Evidence-Based Genotyping and Dosing Strategies
    For resected gastrointestinal stromal tumors (GIST), adjuvant management decisions are based on evidence produced after surgery rather than on findings extrapolated from advanced disease. Tumor genotyping identifies patients who should not receive imatinib: tumors driven by PDGFRA D842V mutations, succinate dehydrogenase–deficient tumors, and neurofibromatosis type 1–associated tumors do not respond to imatinib, sparing these patients an ineffective drug.
    For imatinib-sensitive tumors judged to be at high risk of recurrence by modified National Institutes of Health (NIH) or Armed Forces Institute of Pathology (AFIP) criteria, the regimen tested in randomized adjuvant trials is adjuvant imatinib at 400 mg daily for three years. Although the advantage of escalating to 800 mg daily was shown in advanced disease, adjuvant cohorts examining this question found no benefit from dose escalation after resection for tumors with a KIT exon 9 mutation, leaving post-resection dosing unresolved.
    When the risk of recurrence is highest, continuing imatinib beyond three years delays relapse but has not been shown to cure the disease or prolong survival. Post-resection circulating tumor DNA (ctDNA) testing remains under study and is not yet part of routine care. The authors emphasize weighing genotype, clinicopathological risk schemes, and prognostic factors omitted from standard schemes together to individualize care and offer clinical trial enrollment whenever available.

    Key Takeaways

    • Adjuvant cohorts evaluating tumors with a KIT exon 9 mutation found no benefit from dose escalation to 800 mg daily after surgical resection.
    • Tumors driven by PDGFRA D842V mutations, succinate dehydrogenase deficiency, or neurofibromatosis type 1 do not respond to imatinib, sparing these patients an ineffective drug.
    • Continuing adjuvant imatinib beyond three years in patients at highest risk of recurrence delays relapse but has not been shown to cure the disease or prolong survival.
    Read the original sourceCurrent Treatment Options in Oncology